We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » TAXUS RECALL EXPANDED; COSTS APPROACHING $100M
TAXUS RECALL EXPANDED; COSTS APPROACHING $100M
July 23, 2004
The expanded recall of Boston Scientific’s drug-eluting Taxus stent will result in a nearly $100 million hit on the firm’s second-quarter earnings, company officials confirmed.